MedTrace Logo

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2007-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine if, in men and women with excess abdominal fat and insulin resistance, people with HIV infection respond differently than people without HIV to interventions that typically improve body fat distribution and insulin resistance. The specific interventions are:

1. Diet + exercise program.
2. Rosiglitazone treatment.
3. A combination treatment of diet + exercise program and rosiglitazone.

Conditions

Interventions

BEHAVIORAL

Weight loss through diet and exercise

DRUG

Rosiglitazone insulin sensitizing agent

Sponsors & Collaborators

  • St. Luke's-Roosevelt Hospital Center

    lead OTHER

Principal Investigators

  • Donald P Kotler, MD · St. Luke's-Roosevelt Hospital Center, Columbia University

  • Jeanine B Albu, MD · St. Luke's-Roosevelt Hospital Center, Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264251 on ClinicalTrials.gov